Parabilis’ FDA Alignment Gives Its Desmoid Tumor Program a Clearer Road Map
Parabilis’ FDA-aligned dose strategy and placebo-controlled pivotal trial design may reduce uncertainty around its desmoid tumor program.
American Express’ 5% Workforce Cut Puts Cost Discipline in the Spotlight
American Express will cut 5% of its workforce and record a $336 million restructuring charge after a…
Teva's FDA Approval Adds a Fresh Catalyst for Healthcare Investors
Teva drew attention after an FDA approval, but its quoted price later stood at $40.21, down 1.009%, …
Tango Therapeutics Slides 13% Despite 82% Pancreatic Cancer Response Rate
Tango Therapeutics fell 13% despite an 82% response rate, highlighting how traders discount small-sa…
Elicio’s Pancreatic Cancer Trial Misses Endpoint Despite Positive Subgroup Signal
Elicio’s Phase 2 pancreatic cancer trial missed its primary endpoint, while a subgroup signal raises…
IDEAYA’s IDE849 Data Put Dose, Safety and Pipeline Economics in Focus
IDE849’s Grade 3+ adverse-event rates rose from 5% to 22.2% across doses, sharpening questions about…
Rapport Director Buys Nearly $1 Million as Analyst Raises Price Target to $82
Insider buying and a higher $82 price target put Rapport Therapeutics’ clinical pipeline under the m…
Visa’s Reported Fireblocks Talks Point to a Bigger Crypto Infrastructure Bet
Visa’s reported talks to acquire Fireblocks for about $2.5 billion could signal a deeper push into i…
Biohaven Stock Jumps 25% After FDA Accepts Resubmitted Vyglxia Filing
BHVN jumped 25% after the FDA accepted Biohaven’s resubmitted Vyglxia filing, but acceptance is not …
AstraZeneca Launches Zegfrovy in U.S. After Accelerated FDA Approval
AstraZeneca’s U.S. launch of Zegfrovy opens a potential oncology revenue stream, but accelerated app…